Methylfolate (5-methyltetrahydrofolate, 5-MTHF) is the biologically active, reduced form of folate that serves as the primary methyl donor in the methylation cycle. Unlike synthetic folic acid, methylfolate does not require enzymatic conversion by MTHFR (methylenetetrahydrofolate reductase) and is immediately bioavailable for critical methylation reactions, including homocysteine remethylation, SAMe production, neurotransmitter synthesis, and DNA methylation.
Think of methylfolate as pre-cut keys ready to unlock methylation processes throughout the body, while folic acid is like blank metal slugs that must first be shaped by the MTHFR enzyme before they become functional keys. If you have a MTHFR polymorphism, your key-cutting machine (the enzyme) runs slowly or produces defective keys—meaning you accumulate useless blanks (unmetabolized folic acid) while starving for working keys (methylfolate).
In the methylation factory, methylfolate is the delivery truck carrying methyl groups (CH₃) to critical assembly lines. It pulls up to the homocysteine loading dock, drops off its methyl group (with vitamin B12 as the forklift operator running methionine synthase), and converts toxic homocysteine into methionine—which then gets upgraded into SAMe, the master methyl donor for 200+ reactions. Without enough methylfolate trucks making deliveries, homocysteine waste piles up (neurotoxic), methionine production stops, and downstream methylation assembly lines shut down: neurotransmitters aren't synthesized, DNA can't be properly methylated, myelin sheaths aren't maintained, and cellular repair stalls.
Methylfolate operates at the critical junction between the folate cycle and methylation cycle:
Dietary folate/folic acid
→ Dihydrofolate (DHF)
→ Tetrahydrofolate (THF) [via DHFR]
→ 5,10-methyleneTHF [via SHMT2]
→ 5-methylTHF (methylfolate) [via MTHFR enzyme]
graph TD
A[Methylfolate 5-MTHF] -->|"donates CH₃"| B[Methionine Synthase]
B -->|requires B12 methylcobalamin| C[Homocysteine]
C -->|"receives CH₃"| D[Methionine]
D -->|ATP activation| E[SAMe S-Adenosyl-Methionine]
E -->|methylation reactions| F[SAH S-Adenosyl-Homocysteine]
F -->|hydrolysis| C
E --> G[Neurotransmitter Synthesis]
E --> H[DNA Methylation]
E --> I[Myelin Production]
E --> J[Phospholipid Synthesis]
E --> K[Creatine Synthesis]
C -->|alternative pathway| L["Cysteine + Glutathione"]
M[MTHFR C677T/A1298C] -.->|reduces by 30-70%| A
Detailed Cascade:
- Methyl Donation: Methylfolate (5-MTHF) carries a labile methyl group (CH₃) to the enzyme methionine synthase (MTR)
- B12 Cofactor: Methylcobalamin (active B12) acts as intermediate acceptor, receiving CH₃ from methylfolate → forms methylB12 intermediate
- Homocysteine Remethylation: MethylB12 transfers CH₃ to homocysteine → regenerates methionine
- SAMe Formation: Methionine + ATP → SAMe via methionine adenosyltransferase (MAT)
- Methylation Reactions: SAMe donates CH₃ to >200 substrates:
- DNA methyltransferases (DNMT1, DNMT3a/3b) → epigenetic regulation
- Catechol-O-methyltransferase (COMT) → dopamine/norepinephrine metabolism
- Phosphatidylethanolamine N-methyltransferase → phosphatidylcholine (myelin)
- Guanidinoacetate N-methyltransferase → creatine synthesis
- Histamine N-methyltransferase → histamine degradation
- Recycling: SAMe → SAH (S-adenosylhomocysteine) → homocysteine (via SAH hydrolase) → cycle repeats
MTHFR Polymorphism Impact:
- C677T variant (30-40% population): Reduces MTHFR enzyme activity by 30-70% → decreased methylfolate production from dietary folate
- A1298C variant (up to 12% homozygous): Reduces enzyme stability → impaired folate cycle function
- Compound heterozygotes (C677T + A1298C): Cumulative functional deficiency
Blood-Brain Barrier Transport:
Methylfolate crosses BBB via folate receptor alpha (FR-α) and reduced folate carrier (RFC-1) → preferentially accumulates in CSF (3x plasma concentration) → critical for CNS methylation, neurotransmitter synthesis, and myelin maintenance.
Patient Populations:
- MTHFR polymorphism carriers (genetic testing indicated for treatment-resistant depression, elevated homocysteine, recurrent miscarriage): Require methylfolate supplementation as folic acid is poorly converted
- Elevated homocysteine (>7 µmol/L optimal, >10 µmol/L intervention threshold, >15 µmol/L high risk): Marker of methylation dysfunction—methylfolate + methylcobalamin protocol essential
- Treatment-resistant depression (STAR*D trial showed 30-40% fail first-line SSRIs): Methylfolate augmentation at 7.5-15 mg/day improves serotonin/dopamine synthesis
- Cognitive decline/dementia prevention: Low folate status correlates with hippocampal atrophy, white matter lesions; methylfolate supports myelin integrity
- Cardiovascular disease risk: Homocysteine is independent CVD risk factor (endothelial damage, atherosclerosis)—methylfolate reduces levels
- Pregnancy planning/pregnancy: Prevents neural tube defects (critical first 28 days when neural tube closes); methylfolate superior to folic acid for MTHFR carriers
Folate deficiency represents an evolutionary mismatch: hunter-gatherer diets provided 400-600 µg/day from dark leafy greens, organ meats, fermented foods. Modern processed diets lack bioavailable folate, while folic acid fortification (introduced 1998) provides synthetic form requiring intact MTHFR function. Polymorphisms persist in 30-40% of population because they may have conferred malaria resistance (lower RBC folate → impaired Plasmodium replication).
Brain is folate-greedy: CSF folate concentration maintained at 3x plasma levels via active transport. Under deficiency, brain pulls folate from periphery → peripheral methylation dysfunction (immune cell dysfunction, muscle fatigue, poor wound healing) while protecting CNS. Immune cells also require folate for proliferation—chronic inflammation creates competitive folate demand.
Dosing:
- Maintenance/prevention: 400-1000 µg/day (equivalent to dietary sufficiency)
- MTHFR polymorphism: 1-5 mg/day depending on genotype (C677T homozygotes may need upper range)
- Depression augmentation: 7.5-15 mg/day (L-methylfolate prescription products: Deplin®)
- Elevated homocysteine: 1-5 mg/day combined with methylcobalamin 1000-5000 µg
Essential Co-Factors:
- Methylcobalamin (B12): Absolute requirement—methionine synthase cannot function without B12 cofactor
- Vitamin B6 (P5P): Required for alternative homocysteine pathway (transsulfuration to cysteine)
- Riboflavin (B2): Cofactor for MTHFR enzyme—supplementation can partially rescue C677T function
- Magnesium: Required for methylation cycle enzymes
- Zinc: Cofactor for methionine synthase
Avoid Folic Acid:
- Synthetic form requires DHFR → DHF → THF → 5,10-methyleneTHF → 5-MTHF (MTHFR step is rate-limiting)
- In MTHFR polymorphism carriers, folic acid accumulates unmetabolized in circulation
- Unmetabolized folic acid (UMFA) may block folate receptors, worsen functional deficiency
- UMFA cannot mask B12 deficiency properly (methylfolate trap mechanism requires B12)
Monitoring Biomarkers:
- Plasma homocysteine (target <7 µmol/L)
- RBC folate (functional status, target >900 nmol/L)
- Serum B12 or methylmalonic acid (ensure B12 adequacy)
- Depression/anxiety scales (PHQ-9, GAD-7)
- Cognitive function tests
- Bioavailability: Methylfolate is 7x more bioavailable than folic acid in individuals with MTHFR C677T homozygous genotype
- MTHFR prevalence: C677T variant affects 30-40% Caucasians (10-15% homozygous), up to 20% Hispanics/Asians homozygous; A1298C affects ~12% homozygous
- Homocysteine targets: <7 µmol/L optimal, 7-10 acceptable, 10-15 moderate risk, >15 high risk for cardiovascular events and cognitive decline
- CSF concentration: Brain maintains folate at 3x plasma concentration via active FR-α transport—preferential CNS retention
- Depression trials: L-methylfolate 15 mg/day as SSRI augmentation shows 32% response improvement vs. placebo in treatment-resistant depression
- Neural tube defects: 400 µg/day reduces NTD risk by 70%; methylfolate superior in MTHFR carriers (folic acid fortification has not eliminated all NTDs)
- DNA methylation: Methylfolate deficiency causes global DNA hypomethylation → cancer risk, chromosomal instability, altered gene expression
- Half-life: Plasma methylfolate half-life ~3 hours; requires consistent supplementation
- Safety margin: No established upper limit; doses up to 15 mg/day used safely in clinical trials
- Form specificity: L-methylfolate (6S-isomer) is biologically active; D-form is inactive—ensure supplements specify L-methylfolate or Metafolin®/Quatrefolic® brands
- 5-MTHF — 5-MTHF is the biochemical designation for methylfolate
- MTHFR — methylfolate bypasses MTHFR enzyme bottleneck, essential for polymorphism carriers with reduced conversion capacity
- folate cycle — methylfolate is the final reduced product of the folate cycle
- methylation cycle — methylfolate serves as the primary methyl donor initiating the cycle via homocysteine remethylation
- homocysteine — methylfolate remethylates homocysteine to methionine via B12-dependent methionine synthase, reducing neurotoxic accumulation
- methionine synthase — enzyme that accepts methyl group from methylfolate using methylcobalamin cofactor
- SAMe — methylfolate supports SAMe regeneration via methionine production, enabling 200+ downstream methylation reactions
- folic acid — synthetic oxidized form requiring multi-step enzymatic reduction; methylfolate is superior clinically
- vitamin B12 — methylcobalamin is absolute cofactor requirement for methylfolate function via methionine synthase
- methylation protocol — methylfolate is foundational component alongside methylcobalamin, B6, riboflavin
- DNA methylation — methylfolate supports SAMe-dependent DNA methyltransferases (DNMT1/3a/3b) for epigenetic regulation
- depression — methylfolate augmentation enhances neurotransmitter synthesis (serotonin, dopamine, norepinephrine) via SAMe-dependent enzymes
- cardiovascular disease — methylfolate reduces homocysteine-mediated endothelial dysfunction, oxidative stress, atherosclerosis
- neural tube defects — methylfolate prevents NTDs during first trimester by supporting neural tube closure (days 21-28 post-conception)
- cognitive decline — methylfolate maintains myelin integrity, supports neurotransmitter synthesis, reduces homocysteine neurotoxicity
- BDNF — methylfolate supports BDNF gene methylation patterns and expression via DNA methylation mechanisms
- neuroinflammation — methylfolate deficiency impairs methylation-dependent anti-inflammatory pathways, exacerbates microglial activation
- glutathione — homocysteine transsulfuration pathway (requiring B6) produces cysteine for glutathione synthesis—methylfolate indirectly supports by clearing homocysteine
- epigenetics — methylfolate provides methyl groups for histone methylation (H3K4me3, H3K27me3) and DNA methylation patterns
- pregnancy — methylfolate requirements increase 5-10x during pregnancy for fetal DNA synthesis, placental growth, maternal RBC expansion
- COMT — catechol-O-methyltransferase requires SAMe (dependent on methylfolate) to metabolize dopamine and catecholamines
- myelin — phosphatidylcholine synthesis (major myelin component) requires SAMe-dependent methylation of phosphatidylethanolamine
- inflammation — chronic inflammation increases folate demand for immune cell proliferation, creating competitive deficiency
- mitochondrial dysfunction — methylfolate supports mitochondrial DNA methylation and one-carbon metabolism integration
- Module 2 (Evolutionary Medicine): MTHFR polymorphism, methylation cycle, homocysteine pathophysiology, genetic-intervention framework
- Additional appearances: Depression treatment protocols, cognitive decline prevention, cardiovascular risk reduction, pregnancy optimization